

Surj 32

22. (Amended) [An] The isolated haemopoietin receptor according to claim 21 comprising the amino acid sequence [substantially as] set forth in SEQ ID NO:13.

23. (Amended) [An] The isolated haemopoietin receptor according to claim 21 comprising the amino acid sequence [substantially as] set forth in SEQ ID NO:15.

24. (Amended) [An] The isolated haemopoietin receptor according to claim 21 comprising the amino acid sequence [substantially as] set forth in SEQ ID NO:17.

25. (Amended) [An] The isolated haemopoietin receptor according to claim 21 comprising the amino acid sequence [substantially as] set forth in SEQ ID NO:19.

26. (Amended) [An] The isolated haemopoietin receptor according to claim 21 comprising the amino acid sequence [substantially as] set forth in SEQ ID NO:25.

27. (Amended) [An] The isolated haemopoietin receptor according to claim 21 comprising the amino acid sequence [substantially as] set forth in SEQ ID NO:29.

30. (Canceled)

Please add the following claims:

Surj 33

35. An isolated haemopoietin receptor comprising an amino acid sequence having at least about 90% similarity to the amino acid sequence set forth in any one of SEQ ID NO: 13, 15, 17, 19, 25 and 29, wherein said receptor further comprises the amino acid motif:

Trp Ser Xaa Trp Ser (SEQ ID NO:1)

wherein Xaa is any amino acid.

36. The isolated haemopoietin receptor according to claim 35 wherein Xaa is Asp or Glu.

Surj 34

37. An isolated haemopoietin receptor comprising an amino acid sequence encoded by a nucleotide sequence having at least about 85% identity to the nucleotide sequence set forth in any one of SEQ ID NO:12, 14, 16, 18, 24 and 28, wherein said receptor further comprises the amino acid motif:

Trp Ser Xaa Trp Ser (SEQ ID NO:1)

wherein Xaa is any amino acid.

38. The isolated haemopoietin receptor according to claim 37 wherein Xaa is Asp or Glu.

Surj 35

39. An isolated haemopoietin receptor comprising an amino acid sequence encoded by a nucleotide sequence which hybridises under high stringency conditions to the nucleotide

Sub 35
sequence set forth in any one of SEQ ID NO:12, 14, 16, 18, 24 and 28, wherein said receptor further comprises the amino acid motif:

Trp Ser Xaa Trp Ser [SEQ ID NO:1]

wherein Xaa is any amino acid.

40. The isolated haemopoietin receptor according to claim 39 wherein Xaa is Asp or Glu.

Sub 36
41. An isolated haemopoietin receptor according to claim 39 wherein said high stringency conditions comprise from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01M to at least about 0.15M salt for hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions.

Sub 37
42. An isolated haemopoietin receptor according to claim 41 wherein the high stringency conditions comprise 0.1xSSC/0.1% (w/v) SDS at 65°C for 30 min for washing conditions.

D3
43. An isolated haemopoietin receptor comprising the amino acid sequence set forth in SEQ ID NO:13.

Sub 38
44. An isolated haemopoietin receptor comprising the amino acid sequence set forth in SEQ ID NO:15.

Sub 39
45. An isolated haemopoietin receptor comprising the amino acid sequence set forth in SEQ ID NO:17.

46. An isolated haemopoietin receptor comprising the amino acid sequence set forth in SEQ ID NO:19.

47. An isolated haemopoietin receptor comprising the amino acid sequence set forth in SEQ ID NO:25.

48. An isolated haemopoietin receptor comprising the amino acid sequence set forth in SEQ ID NO:29.

REMARKS

In the Office Action dated May 16, 2000, claims 20-27 and 30 are under consideration.

In response to the Office Action, Applicants have amended the claims which, when considered with the following remarks, is deemed to place the present application in condition for allowance. No new matter is introduced. Favorable consideration of all pending claims is respectfully requested.